Gilead Sciences (NASDAQ:GILD) Stock Price Expected to Rise, Rothschild & Co Redburn Analyst Says

Key Points

• Rothschild & Co Redburn raised its price target on Gilead to $153 (from $143), implying a potential upside of 28.22%, while multiple brokerages have also boosted targets and the consensus rating is a "Moderate Buy" with an average price target of $128.27.
• Gilead beat Q3 expectations with EPS of $2.47 (vs. $2.16 expected) and revenue of $7.77B (vs. $7.42B), and set FY2025 guidance at 8.05–8.25 EPS, above analysts' current forecast.
• Insiders have been net sellers recently—71,500 shares (~$8.34M) sold over the last three months—while institutional ownership remains high at about 83.67%.

Gilead Sciences (NASDAQ:GILD - Get Free Report) had its price target lifted by equities research analysts at Rothschild & Co Redburn from $143.00 to $153.00 in a report released on Monday,MarketScreener reports. Rothschild & Co Redburn's price objective would indicate a potential upside of 28.22% from the company's current price.

Several other brokerages have also recently issued reports on GILD. Needham & Company LLC reissued a "buy" rating and issued a $133.00 price target on shares of Gilead Sciences in a research note on Friday, October 31st. TD Cowen lifted their price target on Gilead Sciences from $115.00 to $125.00 and gave the company a "buy" rating in a research report on Thursday, October 23rd. BMO Capital Markets raised their target price on shares of Gilead Sciences from $130.00 to $135.00 and gave the company an "outperform" rating in a research note on Monday, October 20th. Royal Bank Of Canada upped their price target on shares of Gilead Sciences from $100.00 to $105.00 and gave the stock a "sector perform" rating in a research note on Friday, October 31st. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $135.00 target price on shares of Gilead Sciences in a report on Friday, October 31st. One analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and three have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $128.27.

Gilead Sciences Stock Up 0.4%

Shares of NASDAQ GILD opened at $119.32 on Monday. The stock has a market capitalization of $148.06 billion, a P/E ratio of 23.74, a PEG ratio of 0.81 and a beta of 0.32. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.32 and a quick ratio of 1.15. Gilead Sciences has a one year low of $86.08 and a one year high of $124.61. The firm's 50 day simple moving average is $116.49 and its two-hundred day simple moving average is $112.26.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.16 by $0.31. The business had revenue of $7.77 billion during the quarter, compared to analyst estimates of $7.42 billion. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The company's revenue was up 3.0% on a year-over-year basis. During the same period in the prior year, the business posted $2.02 earnings per share. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. As a group, analysts expect that Gilead Sciences will post 7.95 EPS for the current fiscal year.

Insider Transactions at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction that occurred on Wednesday, October 15th. The stock was sold at an average price of $118.08, for a total transaction of $295,200.00. Following the sale, the chief financial officer owned 157,055 shares of the company's stock, valued at approximately $18,545,054.40. This trade represents a 1.57% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Johanna Mercier sold 3,000 shares of the company's stock in a transaction dated Wednesday, October 15th. The shares were sold at an average price of $118.08, for a total transaction of $354,240.00. Following the sale, the insider owned 110,193 shares in the company, valued at $13,011,589.44. This represents a 2.65% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 71,500 shares of company stock valued at $8,336,040 over the last three months. Corporate insiders own 0.27% of the company's stock.

Institutional Investors Weigh In On Gilead Sciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. raised its holdings in Gilead Sciences by 1.6% during the 2nd quarter. Vanguard Group Inc. now owns 119,364,226 shares of the biopharmaceutical company's stock valued at $13,233,912,000 after buying an additional 1,893,401 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Gilead Sciences by 2.6% in the 2nd quarter. Geode Capital Management LLC now owns 29,207,662 shares of the biopharmaceutical company's stock worth $3,231,548,000 after acquiring an additional 727,515 shares during the last quarter. Norges Bank purchased a new position in shares of Gilead Sciences during the 2nd quarter worth about $2,150,268,000. Price T Rowe Associates Inc. MD boosted its position in Gilead Sciences by 314.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 14,703,103 shares of the biopharmaceutical company's stock valued at $1,647,484,000 after buying an additional 11,156,382 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in shares of Gilead Sciences by 12.4% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 13,755,481 shares of the biopharmaceutical company's stock valued at $1,541,302,000 after purchasing an additional 1,520,809 shares in the last quarter. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.